Tag Archives: Patent Law

Supreme Court Reverses In Caraco Appeal

Posted on April 17, 2012 by Warren Woessner

Today, in Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk, in an opinion authored by Justice Kagan (a copy can be found at the end of this post), the Court reversed the Fed. Cir.’s divided 2010 decision that an ANDA filer … Continue reading →

Posted in Hatch-Waxman | Tagged , , , , , , , , , , , , , , | 1 Comment

Prometheus Q/A – Which Side Are You On?

Posted on April 12, 2012 by Warren Woessner

A guest post from Robin Chadwick of SLW. During the three weeks since the Supreme Court ruled that certain diagnostic claims are not eligible for patenting, four other patent cases have been impacted by this ruling. The Court is shaping … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , | 1 Comment

Aventis v. Hospira – How to Meet the Therasense Standards

Posted on April 10, 2012 by Warren Woessner

On April 9, 2012, The Fed. Cir. affirmed a holding by the district court that rendered two (then) Sanofi add-on patents on infusion vehicles for docetaxel unenforceable due to inequitable conduct. The inventors, particularly inventor/project manager Fabre, were found to have … Continue reading →

Posted in Inequitable Conduct/Rule 56 | Tagged , , , , , | 2 Comments

Supreme Court Remands In Myriad Appeal

Posted on March 26, 2012 by Warren Woessner

Today, as predicted by many commentators, the Supreme Court set aside the ruling by the Fed. Cir. that claims to isolated DNA sequences that are the BRCA 1 or 2 gene, or fragments thereof, are patentable subject matter. The Supreme … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | 1 Comment